Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Pancreatic Cancer Metastatic 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Cytarabine 4Mitoxantrone 2Cyclophosphamide 2vosaroxin 1thymoglobulin 1plerixafor 1fludarabine phosphate 1fludarabine 1devimistat 1aldesleukin 1Thiotepa 1Tacrolimus 1Stem Cell Transplantation 1Sorafenib 1Rituximab 1Mycophenolic Acid 1Melphalan 1Leyk 1Interleukin-2 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Daunorubicin 1Clofarabine 1Busulfan 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Myeloid × devimistat × Clear all
NCT02484391 2024-09-19

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Wake Forest University Health Sciences

Phase 1 Completed
48 enrolled 13 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡